PDS Biotechnology Stock

PDS Biotechnology ROA

The Return on Assets (ROA) of PDS Biotechnology (PDSB) as of Aug 14, 2026 is -113.12 %. In the previous year, Return on Assets (ROA) was -82.92 % — a change of 36.43% (lower).

ROA

-113.12 %

YoY

36.43%

Last updated:

In 2026, PDS Biotechnology's return on assets (ROA) was -113.12 %, a 36.43% increase from the -82.92 % ROA in the previous year.

Access this data via the Eulerpool API
Get Free API Key

PDS Biotechnology Stock analysis

What does PDS Biotechnology do? PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology is one of the most popular companies on Eulerpool.

ROA Details

Understanding PDS Biotechnology's Return on Assets (ROA)

PDS Biotechnology's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing PDS Biotechnology's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider PDS Biotechnology's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in PDS Biotechnology’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about PDS Biotechnology stock

Return on Assets (ROA) of PDS Biotechnology is -113.12 % in 2026.

Return on Assets (ROA) of PDS Biotechnology changed from -82.92 % to -113.12 %, representing a 36.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) PDS Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s PDS Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API
Get Free API Key

Profitability — PDS Biotechnology

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — PDS Biotechnology